Mimedx Group Inc Dossier - Source-backed chat

Mimedx Group Inc

MDXGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.27

Intrinsic Value $3.85median of 4 methods · middle span $2-$6based on filings through 30 Jun 2026

Market Price $4.64Price as of 1 Oct 2026

OvervaluedIntrinsic value is 17% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $677.1M

Enterprise Value $558.5M

Shares Outstanding 148.3M diluted

Moat Rating None

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MIMEDX is navigating a highly disruptive transition period following the implementation of new Medicare reimbursement policies for skin substitutes at the start of 2026. While the company's Surgical franchise continues to show healthy double-digit growth (+13% in Q1 2026), its Wound segment has been severely impacted, declining 60% year-over-year. Management has responded aggressively by initiating a restructuring plan to generate $40 million in annualized cost savings, aiming for Adjusted EBITDA breakeven by year-end 2026. Although the company maintains a strong balance sheet with $142 million in net cash and has authorized a $100 million share repurchase program, near-term revenue volatility and execution risks surrounding the cost-reduction plan warrant a cautious Hold stance until market dynamics stabilize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$6.60

High · most bullish analyst$8.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Inconsistent implementation of reimbursement rules by Medicare Administrative Contractors (MACs) persists, prolonging market confusion and pricing pressure. Competitors engage in irrational pricing behavior ('fire sale' conditions), further depressing Wound segment margins. The elimination of the Chief Operating Officer role and other cost-cutting measures disrupt sales execution, causing Surgical segment growth to decelerate. Net sales fall below the guided $260 million floor, and the company fails to achieve Adjusted EBITDA breakeven by year-end.

Base CaseCentral scenario

The advanced wound care market slowly adapts to the new Medicare Physician Fee Schedule (PFS) rules, reducing industry-wide confusion. MIMEDX successfully executes its cost-reduction initiatives, capturing its targeted $40 million in annualized savings to return to profitability in the second half of 2026. Surgical segment growth remains robust at low double-digits, offsetting the near-term drag from the Wound segment. Net sales for 2026 land within the guided range of $260 million to $290 million, with Adjusted EBITDA achieving breakeven.

Bull CaseUpside scenario

A decade of university-derived IP, a platform aimed at several large markets at once, and a credentialed research partner willing to put the technology through its paces.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $159.8 million in cash and cash equivalents ($142 million net of debt) as of March 31, 2026, providing substantial financial runway.
Resilient Surgical franchise (+13% YoY in Q1 2026) led by AMNIOFIX and AMNIOEFFECT, demonstrating healthy underlying demand.
Proactive cost-restructuring plan expected to deliver $40 million in annualized savings, positioning the company for a return to profitability.
A $100 million share repurchase authorization signaling management's confidence in long-term value and capital return capacity.
Differentiated product pipeline with the commercial launch of CHORIOFIX and ongoing clinical trials (EPIEFFECT in CAMPAIGN RCT).

Key Investment Risks

Severe near-term disruption in the Wound segment (-60% YoY in Q1 2026) due to Medicare reimbursement policy changes.
Gross margin compression (declining to 71% in Q1 2026 from 81% in the prior year period) driven by lower Wound pricing and unfavorable product mix.
Execution risk associated with the restructuring plan and the elimination of key operational roles (e.g., Chief Operating Officer).
Inconsistent rule enforcement by Medicare Administrative Contractors (MACs) creating prolonged market uncertainty.
Potential for irrational pricing behavior by competitors in the advanced wound care space.

Thesis Invalidation Triggers

Full-year 2026 net sales falling below the revised guidance range of $260 million to $290 million.
Failure to achieve Adjusted EBITDA breakeven or positive net income in the second half of 2026.
A deceleration of Surgical segment growth to single digits.
Further adverse regulatory or reimbursement changes targeting placental-based biologics.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.